VIP and tolerance induction in autoimmunity
Vasoactive intestinal peptide (VIP) is a potent antiinflammatory agent with immunoregulatory properties, skewing the immune response to a Th2 pattern of cytokine production. Here, we studied the effect of treatment with VIP in the development of diabetes in nonobese diabetic (NOD) mice, an annual mo...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | SER |
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_00778923_v1070_n_p525_Rosignoli |
| Aporte de: |
| Sumario: | Vasoactive intestinal peptide (VIP) is a potent antiinflammatory agent with immunoregulatory properties, skewing the immune response to a Th2 pattern of cytokine production. Here, we studied the effect of treatment with VIP in the development of diabetes in nonobese diabetic (NOD) mice, an annual model of type 1 diabetes. Mice treated with VIP from 4 weeks of age did not develop diabetes and showed milder insulitis than nontreated mice. The protective mechanism of VIP was associated with a reduction in the circulating levels of Th1 cytokines. In the pancreas of VIP-treated animals, regulatory T cell markers predominate, as indicated by the upregulation of FoxP3 and transforming growth factor-β (TGF-β), and the downregulation of the transcription factor, T-bet. These findings indicate that VIP restores tolerance to pancreatic islets by promoting the local differentiation and function of regulatory T cells. © 2006 New York Academy of Sciences. |
|---|